Trace Biosciences Inc. has obtained IND approval from the FDA for LGW16-03 (Nervetrace Dx), the company’s first nerve-specific fluorescent imaging agent. The IND clearance enables Trace to initiate a first-in-human study evaluating the safety and intraoperative performance of LGW16-03 in surgical settings.

In two separate studies, researchers have identified how peripheral nerve injury can lead to increased pain sensitivity. The studies were published on May 25, 2022, in Nature and May 26, 2022, in Science, respectively. The mechanisms they identify could lead to new therapeutic approaches to chronic pain and/or pain hypersensitivity.